Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 11/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248885 | 0.76 | LMNA (0.35) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL1246144 | 0.76 | LMNA (0.39) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL7518490 | 0.76 | LMNA (0.39) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL1249107 | 0.76 | MTNR1A (0.39) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL9030868 | 0.76 | LMNA (0.35) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL7414781 | 0.76 | LMNA (0.35) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL8769693 | 0.76 | LMNA (0.35) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL3691734 | 0.72 | LMNA (0.55) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL9030241 | 0.72 | P2RX4 (0.37) | LMNAMAPK1P2RX4P2RX1P2RX3 | |
| SCHEMBL3732224 | 0.72 | P2RX4 (0.35) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861420-B2 | N-substituted 1,2,4,5-tetrahydro-1H-benzo[d]azepine compounds | PHARMACIA & UPJOHN COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1451176-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030149024-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-08-07 | — | — | US | disclosed |
| WO-2003045940-A2 | BENZAZEPINE DERIVATIVES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149024-A1 | Therapeutic compounds | REN, HMGCR, RPS4X | LMNA 2745/4885TSHR 1091/4885MAPK1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.